Schizophrenia is a condition that affects people’s mental health in many different ways. For example, it can affect a person’s mood and behaviour. It can also affect the way a person thinks, their memory and mental function (cognitive impairment). There is no current treatment for cognitive impairment associated with schizophrenia.

With the aim of addressing this, researchers conducted the Connex clinical study, aimed at evaluating if a study medication (Iclepertin), taken once a day in addition to current prescribed Schizophrenia medication, can improve some of the common cognitive symptoms of Schizophrenia.

The hope for the study is that the medication will improve cognition in people with Schizophrenia and will show to be safe and affective.

The Study enrolled approx. 1758 participants with Schizophrenia at study centers around the world.  The Connex study was a phase 3 trial, meaning the study medication had already been tested for the treatment of  cognitive symptoms in a smaller population of patients with Schizophrenia.

The study is now closed to recruitment.